Department of Surgery, University of Tennessee College of Medicine Chattanooga, TN, USA.
Department of Orthopedic Surgery, University of Tennessee College of Medicine Chattanooga, TN, USA.
Am Surg. 2023 Apr;89(4):984-989. doi: 10.1177/00031348211054066. Epub 2021 Nov 8.
Surgical correction of pectus excavatum by Nuss procedure, commonly referred to as minimally invasive repair of pectus excavatum (MIRPE), often results in significant postoperative pain. This study investigated whether adding intraoperative methadone would reduce the postoperative opioid requirement during admission for patients undergoing MIRPE.
A retrospective cohort chart review was conducted for 40 MIRPE patients between 2018 and 2020. Patients were stratified into 2 groups: those who received multimodal anesthesia (MM, n = 20) and those who received multimodal anesthesia with the addition of intraoperative methadone (MM + M, n = 20). Data collected included total opioid consumption during hospital stay (morphine milligram equivalents [MMEs]), hospital length of stay (LOS), pain scores, time to ambulation, and time to tolerating solid food.
Addition of intraoperative methadone for patients undergoing MIRPE significantly reduced postoperative opioid requirements (MME/kg) during admission ( = .007). On average, patients in the MM group received 1.61 ± .55 MME/kg while patients in the MM + M group received 1.16 ± .44 MME/kg. Hospital opioid (non-methadone) total was also significantly reduced between the MM (1.87 ± .54) and MM + M group (1.37 ± .46), = .003. There was no significant difference in hospital opioid total MME/kg administered between the groups. There were no significant differences observed in hospital LOS, pain scores, time to ambulation, or time to toleration of solid food.
Incorporating intraoperative methadone for patients undergoing MIRPE reduced postoperative opioid requirements and hospital opioid (non-methadone) totals without a significant change in pain scores. Patients undergoing the Nuss procedure may benefit from the administration of intraoperative methadone.
Nuss 手术矫正漏斗胸,通常被称为微创漏斗胸修复术(MIRPE),常导致术后明显疼痛。本研究旨在探讨术中给予美沙酮是否会减少接受 MIRPE 患者住院期间的术后阿片类药物需求。
回顾性分析了 2018 年至 2020 年期间 40 例接受 MIRPE 的患者的病历。患者分为 2 组:接受多模式麻醉(MM)的患者(n = 20)和接受多模式麻醉加术中美沙酮的患者(MM + M,n = 20)。收集的数据包括住院期间的总阿片类药物消耗量(吗啡毫克当量 [MME])、住院时间(LOS)、疼痛评分、下床时间和耐受固体食物的时间。
接受 MIRPE 的患者术中加用美沙酮可显著减少术后阿片类药物的需求(MME/kg)( =.007)。MM 组患者平均接受 1.61 ±.55 MME/kg,而 MM + M 组患者接受 1.16 ±.44 MME/kg。MM 组(1.87 ±.54)和 MM + M 组(1.37 ±.46)的医院阿片类药物(非美沙酮)总量也显著减少, =.003。两组间医院阿片类药物 MME/kg 总用量无显著差异。两组间住院时间、疼痛评分、下床时间和耐受固体食物的时间无显著差异。
接受 MIRPE 的患者术中给予美沙酮可减少术后阿片类药物的需求和医院阿片类药物(非美沙酮)的总量,而疼痛评分无显著变化。接受 Nuss 手术的患者可能受益于术中给予美沙酮。